392 related articles for article (PubMed ID: 22894615)
41. Class D β-lactamases: a reappraisal after five decades.
Leonard DA; Bonomo RA; Powers RA
Acc Chem Res; 2013 Nov; 46(11):2407-15. PubMed ID: 23902256
[TBL] [Abstract][Full Text] [Related]
42. Past and Present Perspectives on β-Lactamases.
Bush K
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061284
[TBL] [Abstract][Full Text] [Related]
43. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options.
Jean SS; Lee WS; Lam C; Hsu CW; Chen RJ; Hsueh PR
Future Microbiol; 2015; 10(3):407-25. PubMed ID: 25812463
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of extended-spectrum beta-lactamases in South America.
Villegas MV; Kattan JN; Quinteros MG; Casellas JM
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():154-8. PubMed ID: 18154539
[TBL] [Abstract][Full Text] [Related]
45. Faecal carriage of ESBL-producing Enterobacteriaceae and carbapenem-resistant Gram-negative bacilli in community settings.
Villar HE; Baserni MN; Jugo MB
J Infect Dev Ctries; 2013 Aug; 7(8):630-4. PubMed ID: 23949299
[TBL] [Abstract][Full Text] [Related]
46. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
47. Detection of gram-negative β-lactamase producing pathogens in the clinical lab.
Thomson KS
Curr Pharm Des; 2013; 19(2):250-6. PubMed ID: 22894616
[TBL] [Abstract][Full Text] [Related]
48. What are extended-spectrum beta-lactamases?
Sutton SS
JAAPA; 2014 Mar; 27(3):14-7. PubMed ID: 24566339
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of multidrug-resistant gram-negative bacilli producing extended-spectrum β-lactamases (ESBLs) and ESBL genes in solid organ transplant recipients.
Men TY; Wang JN; Li H; Gu Y; Xing TH; Peng ZH; Zhong L
Transpl Infect Dis; 2013 Feb; 15(1):14-21. PubMed ID: 23013385
[TBL] [Abstract][Full Text] [Related]
50. IRT and CMT beta-lactamases and inhibitor resistance.
Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
[TBL] [Abstract][Full Text] [Related]
51. Epidemiology and genetic characteristics of extended-spectrum β-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities.
Tinelli M; Cataldo MA; Mantengoli E; Cadeddu C; Cunietti E; Luzzaro F; Rossolini GM; Tacconelli E
J Antimicrob Chemother; 2012 Dec; 67(12):2982-7. PubMed ID: 22865381
[TBL] [Abstract][Full Text] [Related]
52. Restriction of cephalosporins and control of extended spectrum beta-lactamase producing gram negative bacteria in a neonatal intensive care unit.
Murki S; Jonnala S; Mohammed F; Reddy A
Indian Pediatr; 2010 Sep; 47(9):785-8. PubMed ID: 21048261
[TBL] [Abstract][Full Text] [Related]
53. Resistance in gram-negative bacteria: enterobacteriaceae.
Paterson DL
Am J Med; 2006 Jun; 119(6 Suppl 1):S20-8; discussion S62-70. PubMed ID: 16735147
[TBL] [Abstract][Full Text] [Related]
54. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
Jones RN; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
[TBL] [Abstract][Full Text] [Related]
55. Proliferation and significance of clinically relevant β-lactamases.
Bush K
Ann N Y Acad Sci; 2013 Jan; 1277():84-90. PubMed ID: 23346859
[TBL] [Abstract][Full Text] [Related]
56. Mechanisms of resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish hospital.
Briñas L; Lantero M; de Diego I; Alvarez M; Zarazaga M; Torres C
J Antimicrob Chemother; 2005 Dec; 56(6):1107-10. PubMed ID: 16239288
[TBL] [Abstract][Full Text] [Related]
57. Beta-lactamases: current situation and clinical importance.
Garau J
Intensive Care Med; 1994 Jul; 20 Suppl 3():S5-9. PubMed ID: 7962990
[TBL] [Abstract][Full Text] [Related]
58. Regulation of beta-lactamase induction in gram-negative bacteria: a key to understanding the resistance puzzle.
Niemeyer DM
Mil Med; 1994 Dec; 159(12):732-5. PubMed ID: 7723996
[TBL] [Abstract][Full Text] [Related]
59. [The rise of resistant gram-negative bacteria].
Kuijper EJ; van Dissel JT
Ned Tijdschr Geneeskd; 2010; 154(45):A2868. PubMed ID: 21118590
[TBL] [Abstract][Full Text] [Related]
60. Extended spectrum beta-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania.
Ndugulile F; Jureen R; Harthug S; Urassa W; Langeland N
BMC Infect Dis; 2005 Oct; 5():86. PubMed ID: 16225701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
